Current Cancer Drug Targets

Ruiwen Zhang 
Texas Tech University Health Sciences Center
1300 Coulter Drive
Amarillo, TX 79106
USA

Back

RAS Pathways in Prostate Cancer - Mediators of Hormone Resistance?

Author(s): H. C. Whitaker, D. E. Neal.

Abstract:

Although not frequently mutated in prostate cancer Ras isoforms play a pivotal role in multiple pathways that have been implicated in prostate cancer progression to androgen independence. These have included growth factor and cytokine induced activation of the androgen receptor and its coregulators by post translational modification. Current evidence suggests that Ras is also required for androgen receptor activation in hormone sensitive cells. More recently Ras has been shown to work synergistically with other pathways to promote prostate tumorigenesis. We review the multiple lines of evidence implicating Ras as therapeutic target in androgen dependent and independent prostate cancer.

Keywords: Androgen receptor, growth factor, signal transduction, anti-androgen, dihydrotestosterone, GTPases, LNCaP prostate cancer, keratinocyte growth, Interleukin-6, LYRIC/AEG-1, protein EZH2, forskolin, SRC3/AIB1, ERK

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

VOLUME: 10
ISSUE: 8
Year: 2010
Page: [834 - 839]
Pages: 6
DOI: 10.2174/156800910793358005
Price: $58